title: Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
abstract: BACKGROUND
  Lymphocyte recovery after autologous stem cell transplantation (ASCT) has been shown to be associated with positive clinical outcome in non-Hodgkin's lymphoma (NHL). This study sought to identify variables that affect lymphocyte recovery and survival after ASCT.
  
  
  METHODS
  A retrospective analysis of outcomes in 97 consecutive patients with NHL who underwent ASCT in a single center from August 1999 to January 2008 was conducted.
  
  
  RESULTS
  A significant relationship was not observed between infused lymphocyte count and days to recovery of absolute lymphocyte count 500 x 10(6)/L or greater after ASCT (ALC500; r = 0.139, p = 0.176), but there was a significant inverse correlation between infused CD34+ cell count and days to ALC500 (r = -0.333, p = 0.001). Univariately, infused CD34+ cell count and recovery of ALC500 by 20th day after ASCT were significant predictors of survival. The median overall survival (OS) and event-free survival (EFS) were significantly longer in patients who received 8.2 x 10(6) CD34+ cells/kg or more than in those who received fewer than 8.2 x 10(6) CD34+ cells/kg (OS, not reached vs. 11.6 months, p = 0.001; EFS, not reached vs. 4.8 months, p = 0.003). Multivariate analysis confirmed that infused CD34+ cell count was an independent prognostic factor for OS (p = 0.017) and EFS (p = 0.002).
  
  
  CONCLUSIONS
  These data suggest that infused CD34+ cell count is predictive of kinetics of lymphocyte recovery after ASCT and is an independent prognostic factor for OS and EFS after ASCT in patients with NHL.
authors.affiliation: Department of Oncology, Laboratory Medicine, and Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Dok Hyun
authors.initials: DH
authors.lastname: Yoon
authors.forename: Byeong Seok
authors.initials: BS
authors.lastname: Sohn
authors.forename: Geundoo
authors.initials: G
authors.lastname: Jang
authors.forename: Eun Kyoung
authors.initials: EK
authors.lastname: Kim
authors.forename: Byung Woog
authors.initials: BW
authors.lastname: Kang
authors.forename: Chul
authors.initials: C
authors.lastname: Kim
authors.forename: Jeong-Eun
authors.initials: JE
authors.lastname: Kim
authors.forename: Shin
authors.initials: S
authors.lastname: Kim
authors.forename: Dae Ho
authors.initials: DH
authors.lastname: Lee
authors.forename: Jung-Shin
authors.initials: JS
authors.lastname: Lee
authors.forename: Seo-Jin
authors.initials: SJ
authors.lastname: Park
authors.forename: Chan-Jeoung
authors.initials: CJ
authors.lastname: Park
authors.forename: Jooryung
authors.initials: J
authors.lastname: Huh
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000706:statistics & numerical data*; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014182:Transplantation, Autologous / Q000379:methods / Q000706:statistics & numerical data; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018952:Antigens, CD34